Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.5152W HIGH $69.00
Volume
118.72 K
Value Traded
1.09 M
Short % Float
1.43%
+1.52%Week
+30.43%1 Month
+45.54%3 Month
-77.2%6 Month
+8,070%5 Year
+8,070%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.63 B
EPS (TTM)
0.72
P/E Ratio
10.21
Ent. Value
12.76 B
Total Shares
494.49 M
Float Shares
56.10 M
Insiders
88.68%
Institutions
0.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RGC Catalyst Timeline
Dated clinical, regulatory and corporate events for Regencell Bioscience Holdings Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Regencell Bioscience Holdings Limited
14Total events
0Upcoming
3Tier-1 (high impact)
2021 to 2026Coverage
Event history 14
▼Equity OfferingCorporate
Closing of registered direct offering of ordinary shares for approximately $20.0 million
▼Equity OfferingCorporate
Registered direct offering of 985,222 ordinary shares at $20.30 per share for gross proceeds of ~$20M
▲Interim AnalysisTrial
Interim results from second efficacy trial of standardized TCM formulae for ADHD and ASD
ADHD and ASDsource ↗
▲Topline ReadoutCOV19TMClinical Data
Topline results announced: 97.3% of patients had symptoms eliminated within 6 days
COVID-19source ↗
▼Equity OfferingCorporate
Partial exercise of underwriter's over-allotment option for 325,000 additional shares
●IpoCorporate
Pricing of initial public offering of 2,300,000 ordinary shares at $9.50 per share
Past FDA Catalysts and PDUFA Decisions
How RGC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every RGC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Regencell's standardized TCM formulae | ADHD and ASD | 2022-09-12 | Percentage improvement of patients ranged between 14%Read More | Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial - The Sik-Kee Au TCM Brain Theory Assessment for ADHD and ASD (" SKATBT-A 3 "), wRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LO WILLIAM WING YAN DRDirector | Disposition | -70,600 521,630 held | $0.00 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RGC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RGC for Q2 2026. | ||||
RGC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RGC ranks across every disease it competes in
Competitive Position is a premium feature
See how RGC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRGC News
RGCRegencell Bioscience Holdings Limited Announces Closing of Registered Direct Offering of Ordinary Shares
Regencell Bioscience Holdings Limited has successfully completed a registered direct offering of approximately $20 million, primarily led by a substantial investment from a new institutional investor. The offering involved the sale of 985,222 ordinary shares at a purchase price of $20.30 per share. This capital infusion is expected to enhance the company's research and commercialization efforts, particularly in Traditional Chinese Medicine for neurocognitive disorders. The offering was executed under a previously filed shelf registration statement with the SEC.
Read more →RGCRegencell Bioscience Holdings Limited Announces Registered Direct Offering of Ordinary Shares
Regencell Bioscience Holdings Limited has announced a registered direct offering of approximately 985,222 ordinary shares at a price of $20.30 per share, totaling an expected gross proceeds of $20 million. This financing is led by a new institutional investor and is set to close on May 20, 2026, subject to customary conditions. The funds will support the company's initiatives in developing traditional Chinese medicine therapies for neurocognitive disorders, such as ADHD and autism. The offering is pursuant to an effective shelf registration statement filed with the SEC.
Read more →RGC▼ -7%on this news
Regencell Bioscience Holdings Limited Announces First Half 2026 Management Financial Results
Regencell Bioscience Holdings Limited reported its unaudited financial results for the six months ending December 31, 2025. The company experienced a significant increase in net loss, which went up by 187% compared to the same period the previous year. Total operating expenses also saw a sharp rise of 170%, primarily driven by a substantial increase in administrative costs. Additionally, the company's total assets decreased markedly, reflecting a challenging financial environment.
Read more →RGC▼ -9.1%on this news· ran to +20% by day 3
Regencell Bioscience Holdings Limited Announces At-the-Market Offering of Ordinary Shares
Regencell Bioscience Holdings Limited has announced the initiation of an at-the-market offering of ordinary shares, which may raise up to $500 million. The offering is facilitated through a sales agreement with Univest Securities, LLC as the sales agent. The company intends to use the proceeds primarily for working capital and general corporate purposes. The registration for the offering has been filed with the U.S. SEC, and prospective investors are encouraged to review the relevant prospectus for more details.
Read more →RGC▲ +7.6%on this news
FORM OF Fifth EXTENSION OF letter of Lock-Up Undertaking Date: From: (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this forth extension of the letter of lock-up und
Regencell Bioscience Holdings Limited has announced the fifth extension of a lock-up undertaking, extending the lock-up period for an additional twelve months until April 20, 2027. During this extended period, the option holder is allowed to transfer a specified percentage of vested options. The agreement will be governed by the laws of New York. No significant changes or developments affecting the company have been reported alongside this extension.
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2025 Management Financial Results
Regencell Bioscience Holdings Limited has released its unaudited financial results for the first half of 2025, reflecting continued challenges. The company reported a net loss of $1,853,613, a slight improvement from a loss of $2,185,893 in the same period a year earlier. Total assets decreased to $7,479,191 from $8,438,211, while total operating expenses also declined, indicating cost management efforts. Despite these adjustments, the losses indicate ongoing financial struggles for the company.
Read more →RGC▲ +30%on this news· ran to -60% by day 3
Regencell Bioscience Holdings Limited Announces the Forward Stock Split is Effected
Regencell Bioscience Holdings Limited has announced a 38-for-one forward stock split, granting shareholders 37 additional shares for every share they hold on the record date. There will be no changes to the company's name, CUSIP, or trading symbol, and no action is required by shareholders to receive their additional shares. The company's strategic focus remains on the research and development of traditional Chinese medicine for treating neurocognitive disorders, such as ADHD and Autism Spectrum Disorder.
Read more →RGC▼ -14.7%on this news· ran to -31% by day 1
Regencell Bioscience Holdings Limited Announces
Regencell Bioscience Holdings Limited has announced a 38-for-one forward stock split approved by its board of directors. Shareholders of record as of June 12, 2025, will receive 37 additional shares for each share held. The stock split aims to enhance liquidity and make shares more accessible to investors. Following the split, trading is expected to resume at market open on June 16, 2025, with no changes to the company's name or trading symbol.
Read more →RGCFORM OF FORTH EXTENSION OF LETTER OF LOCK-UP UNDERTAKING Date: From: (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this forth extension of the letter of lock-up und
Regencell Bioscience Holdings Limited has announced a fourth extension of a lock-up undertaking for a period of 15 months, extending the agreement until April 20, 2026. This extension involves an agreement between the Optionee and the Company, ensuring compliance under New York law for interpretation and enforcement. No significant positive or negative events were noted beyond the extension itself.
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2024 Financial Results
Regencell Bioscience Holdings Limited announced its financial results for the first half of 2024, revealing a significant decrease in operating expenses by approximately 33%, totaling around $2.3 million. The company reported a net loss of approximately $2.2 million, a decrease of 34% from the previous year. Cash reserves improved notably, with an increase from $1.6 million in June 2023 to approximately $4.8 million as of December 31, 2023. The decrease in operating expenses was largely driven by lower costs in research and development and general administration.
Read more →RGCFORM OF LETTER OF LOCK-UP UNDERTAKING Date: From: (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this third extension of letter of lock-up undertaking (this " Third
Regencell Bioscience Holdings Limited has announced a third extension of a lock-up undertaking, extending the period during which certain options and shares cannot be sold. The extension will last for an additional twelve months, effective until January 20, 2025. This extension reinforces the company's efforts to maintain market stability and manage share distribution following their initial public offering. The agreement is governed by New York laws, ensuring consistency in interpretation and enforcement.
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2023 Management Financial Results
Regencell Bioscience Holdings Limited revealed its unaudited financial results for the first half of 2023, reporting a net loss of $3,315,240. Despite a slight decrease in losses compared to the previous year, the company continues to incur high operating expenses. Regencell focuses on developing and launching Traditional Chinese Medicine (TCM) formulae for neurocognitive disorders. However, the absence of comprehensive clinical trial data poses a challenge for broader acceptance of their treatments.
Read more →RGC▲ +22.1%on this news
SECOND EXTENSION OF letter of Lock-Up Undertaking Date: ____________________ From: ____________________ (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this second ex
Regencell Bioscience Holdings Limited has announced a second extension of its lock-up undertaking agreement. The optionee has agreed to extend the lock-up period for an additional six months, which will now last until January 20, 2024. This extension aims to provide stability and prevent the premature sale of shares, thus supporting shareholder confidence post-IPO. The terms are governed by New York law.
Read more →RGC▲ +6.5%on this news
letter of Lock-Up Undertaking Date: __________________ From: __________________ (the " Optionee ") To: Regencell Bioscience Holdings Limited (the " Company ") References are made in this letter (this " Letter ") to (i) a
Regencell Bioscience Holdings Limited issued a letter of Lock-Up Undertaking, which includes an extension of the lock-up period for an additional six months. This extension follows an agreement allowing the purchase of ordinary shares by an Optionee. The arrangement prevents the sale or transfer of options, which may contribute to stability in the company's shareholder base. The agreement is governed by New York law, adding a layer of legal oversight.
Read more →RGCRegencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial - The Sik-Kee Au TCM Brain Theory Assessment for ADHD and ASD (" SKATBT-A 3 "), w
Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial HONG KONG, September 12, 2022--(Business Wire)--Regencell Bioscience Holdings Limited (Nasdaq: RGC) ("Regencell") today announced its inte
Read more →RGCRegencell Bioscience Holdings Limited Announces First Half 2022 Management Financial Results
Regencell Bioscience Holdings Limited Announces First Half 2022 Management Financial Results HONG KONG, June 2, 2022 - Regencell Bioscience Limited (Nasdaq: RGC) (the "Company"), today announced its unaudited interim financial results for the six months ended December 31, 202
Read more →RGCRegencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19 TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Tre
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period Results of EARTH efficacy trial EARTH Eff
Read more →RGCFORM OF LETTER OF LOCK-UP UNDERTAKING Date
FORM OF LETTER OF LOCK-UP __________________ (the "Optionee") Pursuant to an agreement of option to purchase ordinary share of Regencell Bioscience Holdings Limited dated June 9, 2021, the Company granted to the Optionee certain options (the "Options") to purchase ordinary sh
Read more →RGC▲ +14.5%on this news
Regencell Bioscience's Investigational Liquid-Formula RGC-COV19 TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Effica
Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial Hong Kong, February 17, 2022 - Regencell Bioscien
Read more →RGCRegencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors Hong Kong
Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors Kong, December 13, 2021 - Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and co
Read more →About Regencell Bioscience Holdings Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next RGC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime